Login
Companies $ALLO
$0.81 +$0.00 (0.37%) After hours
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

allogene.com

What Do They Do?

Develops ready-to-use, engineered immune-cell candidates from healthy donors for patients with cancer or autoimmune diseases.

Who Are Their Customers?

Allogene works through collaboration and license agreements with partners such as Servier; agreements can cover licenses, research and development, clinical manufacturing, and product supply.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −22% (Loss)
vs −$41.4M in Q3 FY2025
  • Sep 2, 2026 CFO Geoffrey Parker announced his retirement His departure from all company roles is effective November 6, 2026.
  • May 28, 2026 Zachary Roberts became CEO, replacing David Chang The change took effect July 1, 2026; Chang remains on the board.
  • May 13, 2026 Allogene terminated its Overland license agreement The license covered four targets across Greater China, Taiwan, South Korea and Singapore; no termination payments were made.

Expanded into autoimmune disease The older report describes a cancer-focused pipeline, while the latest report also develops engineered cell candidates for autoimmune diseases.

Who Do They Compete With?

Competes with AstraZeneca, Atara Biotherapeutics, Beam Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Editas Medicine, Fate Therapeutics, Gilead Sciences, Imugene, Intellia Therapeutics, Legend Biotech, Precision Biosciences, Sana Biotechnology, Novartis, Bristol-Myers Squibb, and Autolus Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support